Category Archives: Psoriasis

Ayurvedic Treatment for Psoriasis and Fungal Infections | Auyshman Bhava
Ayushman Bhava is an exclusive Program by CVR Health TV in which Ayurvedic Specialists and Doctors give solutions to the health problems. Watch CVR Health, the 24/7 health channel with doctors...

By: CVR Health TV

See more here:
Ayurvedic Treatment for Psoriasis and Fungal Infections | Auyshman Bhava - Video

Living with Psoriasis is more than skin deep

New online psoriasis resource launched following research findings

29 October 2014 - Living with psoriasis can affect many aspects of your daily life including your overall physiological and emotional health1. To coincide with World Psoriasis Day (29 October) and help people understand and manage their condition more effectively, a new educational website, mypsoriais.co.nz has been launched by AbbVie.

In New Zealand there has been a real need for information specifically for Kiwis, as a survey* by AbbVie revealed many New Zealanders (57% of survey participants) have never accessed any type of online psoriasis support.2 mypsoriasis.co.nz specifically addresses this need by providing a range of support materials including a useful My Journey tab to help patients map their psoriasis journey and learn some of what they can expect as part of living with psoriasis in New Zealand.

Psoriasis is a relatively common autoimmune disease that affects one in 50 New Zealand adults. It is caused by over-activity of the immune system in the skin. It most frequently develops in young adults and continues throughout their life. The most common form of psoriasis causes raised, inflamed, scaly, red skin lesions, known as plaques.1

Dermatologist Dr Steven Lamb says World Psoriasis Day is a really important event in helping raise awareness of an often overlooked condition.

World Psoriasis Day provides a good opportunity to educate the public about psoriasis and highlights what its like living with the condition. It also helps those living with psoriasis realise that there are effective treatments and that they don't have to put up with the symptoms and psychological effects that come with having psoriasis.

The online quantitative survey completed by 492 New Zealanders also found there was a lack of available information on the likely prognosis and implications of psoriasis at diagnosis, with nearly half of survey respondents (49%) indicating that they did not feel they were given sufficient information about the condition and what their diagnosis meant for them.2

Feedback such as this from patients and a lack of awareness in the community about psoriasis were the driving forces behind creating the educational website.

We have a greater understanding now of the psychological and social effects of psoriasis on the individual patients who live with the condition having significant impaired quality of life. Patients have social isolation issues, difficulty maintaining relationships, avoidance of social situations and higher rates of stress and anxiety.

More:
Living with Psoriasis is more than skin deep

Novartis AG (NOVN) won European backing for a treatment against psoriasis that will compete with Amgen Inc.s Enbrel and may garner more than $1 billion in annual sales.

Novartiss secukinumab, which the company plans to sell under the brand name Cosentyx, was recommended by the European Medicine Agencys Committee for Medicinal Products for Human Use, for the treatment of moderate-to-severe plaque psoriasis in adult patients, the Basel, Switzerland-based drugmaker said in a statement today. The European Commission, the EUs executive arm, usually follows the panels advice.

The drug is the first in a class of therapies called interleukin-17A inhibitors to be recommended as a first-line treatment for the skin disease, a malady that afflicts more than 125 million people globally. Cosentyx may earn Novartis $1.1 billion in sales in 2020, according to the average of six analyst estimates compiled by Bloomberg.

In a study, the drug cleared the skin of patients better than Amgens Enbrel, the $4.6 billion-a-year drug that is considered the standard of care. Novartis is also awaiting approval for the drug in the U.S. after a panel of advisers to the Food and Drug Administration voted unanimously last month that secukinumab should be approved by the agency.

To contact the reporter on this story: Simeon Bennett in Geneva at sbennett9@bloomberg.net

To contact the editors responsible for this story: Phil Serafino at pserafino@bloomberg.net Robert Valpuesta, David Risser

Press spacebar to pause and continue. Press esc to stop.

Continue reading here:
Novartis Wins European Backing for Psoriasis Drug Cosentyx

AYURVEDIC TREATMENT ON PSORIASIS AND ITS COMPLICATIONS : BY VAIDYA SAMIR JAMADAGNI SIR.
Ayurvedic panchkarma treatment on advanced stages of psoriasis.

By: Shree Vishwamrut ayurvediya chikitsalaya

Read the original:
AYURVEDIC TREATMENT ON PSORIASIS AND ITS COMPLICATIONS : BY VAIDYA SAMIR JAMADAGNI SIR. - Video

By Cyndi Root

Amgen and AstraZeneca report that a Phase 3 trial of brodalumab has met its primary endpoint and all secondary endpoints in the treatment of moderate-to-severe plaque psoriasis. The two companies announced the results in a press release, stating that the AMAGINE-3 study compared brodalumab to Stelara (ustekinumab) and placebo. Amgen and AstraZeneca are conducting studies of five of Amgens monoclonal antibodies, including brodalumab, under a collaboration agreement initiated in April 2012.

Sean E. Harper, M.D., executive VP of Research and Development at Amgen, said, These results are of particular importance as they are the first to demonstrate superiority to Stelara in achieving total skin clearance, and the second positive pivotal Phase 3 study evaluating brodalumab in patients with moderate-to-severe plaque psoriasis."

Brodalumab

Brodalumab (AMG 827) is a human monoclonal antibody that dampens inflammatory signals by blocking IL-17 ligand binding to the receptor. Influencing the IL-17 pathway and stopping IL-17 ligand binding reduces inflammatory signals, thereby reducing psoriasis. Amgen is also investigating brodalumab for psoriatic arthritis in Phase 3 trials and in Phase 2 asthma trials.

Brodalumab Study

The AMAGINE-3 study compared two doses of brodalumab to Stelara and a placebo in 1,800 patients with moderate-to-severe plaque psoriasis. The study showed that brodalumab was superior to Stelara in achieving total clearance of skin disease, as measured by the Psoriasis Area Severity Index, thereby meeting the trials primary endpoint. Compared to the placebo, brodalumab patients achieved at least a 75 percent improvement from baseline in disease severity at week 12 and clear or almost clear skin. The 210 mg brodalumab group fared better than the 140 mg group, as 36.7 percent achieved skin clearance compared to 27 percent. Both the 210 and 140 mg brodalumab doses proved superior to Stelara patients, as only 18.5 percent achieved skin clearance.

Dr. Harper said, "Despite a variety of treatment options available for psoriasis, many patients still do not meet skin clearance goals. Amgen and AstraZeneca state that they will share results later in the year on the AMAGINE-2 trial evaluating brodalumab versus Stelara.

Stelara

Stelara is a Johnson & Johnson Drug, manufactured by J & Js subsidiary Centocor Ortho Biotech of Horsham, PA. The Food and Drug Administration (FDA) approved Stelara (ustekinumab) in 2009 for moderate to severe psoriasis. Stelara is a monoclonal antibody, a biological treatment that mimics the bodys antibodies and blocks two proteins that cause inflammation.

Read the original post:
Amgen, AstraZeneca Report Phase 3 Brodalumab Meets Endpoints In Psoriasis

Roslyn Heights, NY (PRWEB) November 19, 2014

A shocking number of Americans have psoriasis and eczema39 million adults and childrenwhich is more than four times the population of New York City, the largest city in the US. According to dermatology specialists Dr. Joshua Fox and Dr. Robert Levine with Advanced Dermatology, PC, the seasonal change to cold, dry air creates difficulties for people dealing with these chronic skin disorders.

It is important to manage symptoms, says Dr. Fox, who has served on the board of the National Psoriasis Foundation. Psoriasis and eczema can be painful. They can make everyday actions uncomfortable for adults and children, men and women, and they carry a stigma that can lead to a loss of self-esteem, depression, and other health complications.

Symptoms Psoriasis appears on the skin as red or white, scaly patches that often itch and bleed. The patches can also look scaly or silvery in color. Nails can become yellow, ridged and separate from the nail bed. Up to 30 percent of people with the disease develop psoriatic arthritis, and recent studies indicate that patients with moderate to severe disease are also at increased risk for other associated health conditions, including heart disease, heart attack, diabetes, high blood pressure, obesity, depression and hypertension.

Eczema, a hypersensitivity disease, inflames the skin, causing pain, itching, dryness, swelling, cracking, weeping and scaling. Eczema lesions can bubble, ooze, and crust over if scratched. Skin infections can occur if bacteria invade the skin lesions.

Diagnosis Once patients understand their psoriasis or eczema is not contagious, they seem to be relieved, says Dr. Fox. They are comforted to know there is help for their symptoms.

Psoraisis is an autoimmune disease apparently cause by an overactive immune system that overproduces skin cells. Eczema, on the other hand, is caused by a deficient immune system in which an imbalance of skin proteins creates skin sensitivities. This is a significant distinction because it informs treatment, explains Dr. Fox. A dermatologist will diagnose the condition and provide the most effective care for individual patients.

Psoriasis treatments:

Eczema treatments:

Dr. Foxs and Dr. Levines tips for managing psoriasis and eczema throughout the winter

View original post here:
10 Tips to Manage Psoriasis and Eczema this Winter

Psoriasis Otezla Medicine
You need to talk or ask your doctor for what you need. I am not working for any company and I am not endorsing or selling any products and will not be re-directing you to any websites that...

By: Giup Nguoi Giup Doi

See original here:
Psoriasis Otezla Medicine - Video

Chinese Eczema Once A Day Herbal Treatment Cream for Psoriasis, Atopic Dermatitis
Dr Timothy Haselman PhD MD presents for the indications and directions for the effective Chinese Eczema Ointment by Yang Zhi Herbal Pro Dr Timothy Haselman PhD MD presents for the indications...

By: Sabrina Mixwell

Visit link:
Chinese Eczema Once A Day Herbal Treatment Cream for Psoriasis, Atopic Dermatitis - Video

Psoriasis Eczema : Rain soul by Johnny
Why wait Order now : https://myrainoffice.com/enroll/self_enroll_pc.php?sponsor=125969 Information : http://www.rainsoul2u.com call delivery +6013-373 0101 http://www.myrainlife.com/johnnylee...

By: johnny lee

See original here:
Psoriasis & Eczema : Rain soul by Johnny - Video

FIRST and foremost, psoriasis is NOT a contagious disease. This strong statement hopefully, will remove, once and for all, the prevailing notion that psoriasis is a communicable and contagious disease, a misconception which has directly and indirectly put patients or if you may, sufferers of the disease, into pitiful situations like not being allowed to board a plane or eat in a high-end restaurant or even just being a seatmate in a classroom.

Second fact is that psoriasis is an inherited ailment. There is a trait handed down from parents to children, although not necessarily affecting all siblings. Genetic mutation has also been found to be a cause of the illness. The characteristic triad of psoriasis is thickening, redness and scaling. The extreme redness of the skin gives the impression to onlookers that there might be an infection, thus, their worry and eventual avoidance of close contact with the person.

The skin is now considered as the biggest organ in the human body, in terms of surface area. It has three layers; the epidermis being the outermost, serving as an effective protective barrier not only against microbes but also to harmful solar rays from the sun. The dermis is the middle, thickest and so-called vascular layer, whose blood vessels supply oxygen and nutrients to the overlying epidermis. The subcutaneous layer or tela subcutanea is made of fatty tissue, oleic acid being most abundant fat in it, colored bright orange-yellow because of the pigments carotene and xanthophyll. In normal, healthy individuals, it takes 28-30 days for the process of epidermidization - the replacement of the dead topmost layer of skin cells by new, young skin cells. In the case of persons with psoriasis, this process is much shorter that the skin cell turnover takes place within 3-5 days, thus resulting to an excessive accumulation of dead surface cells which later develop into scales and even bigger plaques. Dry and dead skins cells eventually slough off and shed leaving a fresh, reddish raw skin underneath the scales or plaques. Of course, itchiness or pruritus is a disturbing symptom which would make a person scratch the lesion and this invites infections especially with streptococcus and staphylococcus.

The author has been fortunate to watch the interview of Mr. Joseph de Guzman, President of Philippine Psoriasis Association and the doyenne of the VMV Skin Research Center, Dr. Vermen. M. Verallo-Rowell. The lady dermatologists, known both locally and internationally emphasized the two spikes of the occurrence of psoriasis in the lifetime of humans; the first being 18-25 years and the second spike when the person is 40-50 years old. There are sites of predilection; usually the scaling starts in the scalp, so much that dandruff or seborrheic dermatitis could be mistaken as psoriasis, although the amiable doctor said that the scalp scaling could be part and parcel of the disease. Skin folds particularly the knees and the elbows are also favored sites of psoriasis.

A whole body physical exam under natural light is imperative in the diagnosis of psoriasis, which could be mistaken as eczema, atopic dermatitis, or skin asthma. Contact dermatitis is the redness and inflammation of skin like earlobes wrist or fingers allergic to costume jewelries especially those containing nickel and alloy of metals. The treatment, although both Mr. de Guzman and Dr. Rowell were quite careful about declaring an absolute cure - depends on the extent of body surface involvement; less than 5 percent of the body would be mild, moderate if from 5-10 percent and severe if more than 15 percent of the body is involved in which, on top of the topical creams and lotions, the patient must take capsules or even receive injections to manage the signs and symptoms of psoriasis.

A very endearing and shall we say, nationalistic statement from Dr. Verallo-Rowell, who had extensive training abroad, extolled the virtues of our own coconut oil, especially if freshly-obtained. Zinc oxide applied properly serves as a skin barrier repair. While topical steroid creams significantly reduce the inflammatory skin reactions, Mr. de Guzman was quick to share experiences of his colleagues that more than two-weeks use could lead to thinning of the skin, making it susceptible to bacterial infection. Dr. Rowell encourages patients to get early morning sunshine, and swim in the sea preferably before 9 am and after 4 pm. Swimming pool has chlorine and hydrochloric acid in it so it may not be good for the psoriatic patient. Of course, for the real problematic cases, the cancer medicine Methotrexate or MTX is an effective last resort.

Dr. Verallo-Rowell clarified that a diagnosis of psoriasis is not as morbid as a death toll, sharing experiences with patients who, monitored regularly and obediently took their medicines, have had no flare-ups and in fact, brave and confident enough to walk down the ramp amidst glaring light of fashion shows or the scrutinizing close up on television interviews. More than that, she implored the public not to cast a disdainful look at persons with psoriasis but rather give them a compassionate, accepting and friendly smile.

Let's shake hands to that. Or better yet, why not a beso beso? Cheers!

Next Week: Let's hear it for deafness

Published in the Sun.Star Baguio newspaper on November 15, 2014.

Go here to read the rest:
Dumaguing: Know More about Psoriasis